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Abstract
Surprisingly, most Bordetella parapertussis isolates collected in France since 2007 do not express pertactin, owing to mutations in the
structural gene encoding this protein. We used a 454 pyrosequencing strategy to study and compare the genetics of two B. parapertussis
isolates (one expressing pertactin and one not expressing pertactin) and the reference strain. No region of difference was detected
between the genomes of the two isolates and the genome of the reference strain. No increase in repeated sequences between both
isolates was found, and there were very few sequence differences. Using cellular and animal models, we found no substantial difference
between the pathogenicity of these B. parapertussis isolates, which is consistent with clinical data. The emergence of these isolates, indi-
cating that pertactin expression is not essential for virulence for B. parapertussis, is discussed.
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Introduction
Bordetella pertussis and Bordetella parapertussis are the causa-
tive agents of whooping cough, a disease that is still endemic
worldwide, despite extensive pertussis vaccination of young
children. The reported incidence of B. pertussis disease has
always been higher than that of B. parapertussis all around
the world; however, it differs between regions [1] and age
groups [2]. The genome sequences of B. pertussis and B. par-
apertussis reference strains indicate that these two closely
related human-adapted species have evolved independently
from a Bordetella bronchiseptica-like ancestor [3,4], and that
the association of B. parapertussis with humans may be more
recent than that of B. pertussis [3,5].
B. pertussis and B. parapertussis share several virulence
factors, including the adhesins filamentous haemagglutinin
(FHA) and pertactin (PRN), and the toxins adenylate cyclase–
haemolysin (AC-Hly) and tracheal cytotoxin. B. pertussis,
but not B. parapertussis, expresses pertussis toxin, tracheal
colonization factor and Bordetella resistance to killing factor
[4]. Like B. pertussis, B. parapertussis does not express a type -
III secretion system (TTSS III). It is generally thought that
B. parapertussis infection causes a less severe disease than
B. pertussis infection. However, as observed by Novotny [6],
‘Both species can induce mild or severe disease and no
clinicians in the world could distinguish between the two
infections by clinical symptoms only.’ One other important
difference between the two species, apart from the expres-
sion of pertussis toxin, is the structure of their lipolysaccha-
rides (LPSs) [7]: (i) lipid A does not stimulate toll-like
receptor 4 efficiently, enabling the pathogen to avoid host
immunity [8]; (ii) the O-antigen, which is not expressed by
B. pertussis [4], allows B. parapertussis to colonize the lower
respiratory tract by protecting the pathogen from comple-
ment-mediated control [9], and to avoid B. pertussis-induced
immunity [10]; and (iii) B. parapertussis and B. pertussis LPSs
modulate human dendritic cells differently [11]. Using micro-
arrays, Brinig et al. [5] found that the gene contents of ge-
nomes of human B. parapertussis isolates from patients in nine
countries over several decades differed very little. Indeed, the
B. parapertussis population is highly clonal, as illustrated by the
use of different genotyping techniques [12–14].
B. parapertussis was shown to escape B. pertussis immunity
in animal models [9,10,15] and also in human populations.
Despite high homology between the two species, B. pertussis
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infection or vaccination-induced immunities do not protect
against B. parapertussis infections [16–18].
Many fewer B. parapertussis isolates than B. pertussis iso-
lates were sent to the National Centre of Reference (NCR)
in France between 1995 and 2006 (0–7%, depending on the
year); since 2007, a small increase has nevertheless been
noticed (12.6%). Surprisingly, 95% of B. parapertussis isolates
collected since 2007 do not express PRN. In this study, we
report a 454 pyrosequencing analysis of the genetic contents
of two isolates and investigations of their pathogenicity in
cellular and animal models.
Material and Methods
Clinical isolates, bacterial growth and DNA extraction
The clinical isolates analysed in this study are described in
Table 1. They were characterized using classical bacteriologi-
cal techniques, including growth on Bordet Gengou agar sup-
plemented with 15% sheep blood (BGA), API galleries, oxidase
and urease tests, and detection of brownish pigment. They
were grown at 36C for 72 h on BGA, and subcultured for
24 h in the same medium before use. Genomic DNA for 454
pyrosequencing was extracted on Genomic-tip 500/G anion-
exchange columns (Qiagen GmbH, Hilden, Germany). DNA
for PCR validations was obtained with Dneasy Tissue Kits
(Qiagen), according to the manufacturer’s recommendations.
Pulsed-field gel electrophoresis (PFGE)
DNA fingerprinting by PFGE was performed as previously
described [19].
Genotyping of prn
Genotyping of the prn gene (regions I and II) was performed
as previously described [19].
Western blot analysis
Western blot analysis was performed as described in [15].
Adenylate cyclase activity
Adenylate cyclase activity was measured as previously
described [15].
454 Pyrosequencing
A 454 GS-FLX NextGen sequencing platform (Roche Diagnos-
tics GmbH, Beckman Coulter Genomics, Meylan, France) was
used for pyrosequencing the two genomes and analysis of the
sequences. The two samples were simultaneously sequenced in
one GS-FLX run, using one 70 · 75 mm Pico-Titer plate device
(Roche Diagnostics GmbH) and one GS LR-70 sequencing kit
(Roche Diagnostics GmbH) as previously described [20].
Cell growth conditions
J774-A1 macrophages cells. J774-A1 cells were cultured in
RPMI-1640+ Glutamax (Gibco-BRL, Paisley, UK) supple-
mented with 10% fetal bovine serum (DAP Vogel Grun,
France), 100 U/mL penicillin, 100 mg/L streptomycin and
250 ng/mL amphotericin (Gibco-BRL), 10 mM HEPES (Gibco-
BRL) and 1 mM sodium pyruvate (Gibco-BRL) in 75-mL tis-
sue culture flasks (Corning New York, New York, USA).
Cells were maintained in a 5% CO2 atmosphere at 37C as
previously described [21].
Human tracheal epithelial (HTE) cells. Cells were plated in
tissue culture trays coated with collagen (Biochrom AG, Berlin,
Germany), and cultured in DMEM-Glutamax (Gibco-BRL) sup-
plemented with 2% UltroserG, 100 U/mL penicillin, 100 lg/mL
streptomycin and 250 ng/mL amphotericin (Gibco-BRL), in a
5% CO2 atmosphere at 37C as previously described [21].
Cytotoxicity assays
Cytotoxicity of bacteria against J774-A1 cells was measured
as previously described [21].
Invasion assays
Invasion assays for HTE cells were performed as previously
described [21].
TABLE 1. Characteristics of the isolates used in experiments with cellular and murine models
Identification
of the isolate Expression factor deficiency Collected in:
Age of the
patient
Pertusiss vaccine status
of the patient
12822 None 1993 16 months [26]
BPP1a None 1994 3 months One vaccination
FR0388 None 1997 5 years Unknown
FR3286 None 2003 90 years Non-vaccinated
FR3717 PRN (point deletion in region II of the prn gene) 2007 4.5 years Primary vaccination and one booster
FR3728a PRN (point deletion in region II of the prn gene) 2007 7 years Primary vaccination and one booster
FR3743 PRN (point deletion in region II of the prn gene) 2007 2.5 years Unknown
FR3772 PRN (point deletion in region I of the prn gene) 2007 8 years Unknown
aThe genomes of these two isolates were subjected to 454 GS-FLX pyrosequencing.
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Murine intranasal model of infection
All procedures involving animals were conducted in accor-
dance with the Institut Pasteur animal care and use committee
guidelines. Bacteria were grown on BGA for 72 h and then
subcultured for 24 h before inoculation of the mice. Four-
week-old female Swiss mice (CERJ, Le Genest-St-Isle, France)
were used to determine the behaviour of the bacteria in the
respiratory tract of young mice, as described in [15].
Results
Description of the isolates
Between 1993 and December 2009, 45 human B. parapertus-
sis isolates were collected by the NCR, originating from vari-
ous regions of France. All of the 25 isolates collected up to
2007 expressed AC-Hly, FHA and PRN, as detected in bac-
terial suspensions by the use of immunoblotting with specific
antibodies to the different proteins. Nineteen of the 20 iso-
lates collected since 2007 expressed AC-Hly and FHA but
not PRN, as determined with specific anti-PRN antibodies.
We sequenced regions I and II of the PRN gene, and we
determined amino acid polymorphisms in these regions: all
20 isolates carried allele 4a for region I and allele 9b for
region II in their genomes, consistent with findings for all
PRN-positive isolates collected in France before 2007 [22].
We nevertheless found in the genomes of the 19 PRN-nega-
tive isolates point mutations within region I or region II
(depending on the isolate) of the prn gene, close to the
sequence used to determine amino acid polymorphisms: the
prn gene in all of these isolates was interrupted by stop
codons, because of deletion of a G from position 1835 in
region II or deletion of an A from position 988 in region I,
as compared with the prn gene of the reference strain 12822
(accession numbers: GU384668 and GU384669).
The expression of AC-Hly, FHA and PRN (when
expressed) by B. parapertussis isolates is repressed when cul-
tures are performed in the presence of MgSO4 or nicotinic
acid, which was expected (data not shown).
We also used the PFGE XbaI restriction typing method to
study the isolates (Fig. 1). Most of the B. parapertussis isolates
and one PRN-negative isolate (FR3772), originating from
different regions of the world, and the reference strain 12822
were characterized by profile I. All but one of the PRN-negative
isolates collected since 2007 were characterized by profile II, as
was one PRN-positive isolate, collected in Saint Petersburg [12].
Pyrosequencing data analysis
DNA from one B. parapertussis PRN-positive isolate (BPP1)
collected in 1994 and from one PRN-negative isolate
collected in 2007 (FR3728; Table 1) were used in a 454 py-
rosequencing run (Table 2). No region of difference (RD)
was found between the genomes of the two isolates and the
genome of the reference strain 12822. Only a few sequence
differences were found (Table 2).
Cytotoxicity of the PRN-negative B. parapertussis isolates
towards murine macrophages
FR3728 (PRN-negative) and other (PRN-negative) isolates,
including FR3717 and FR3743, were not cytotoxic to murine
macrophages (J774-A1; data not shown); similarly, the refer-
ence strain Bpp12822 and the PRN-positive isolate BPP1
were not cytotoxic in this assay.
Invasive properties of PRN-negative B. parapertussis isolates
on HTE cells
We investigated the invasive properties of FR3728 (PRN-
negative) and other PRN-negative isolates (FR3717, FR3743
and FR3772), and also of the reference strain Bpp12822 and
other PRN-positive isolates (BPP1, FR0388 and FR3286), in
HTE cells. All PRN-negative isolates were found to be as
invasive as the reference strain 12822 and PRN-positive iso-
lates, except for the PRN-positive isolate BPP1, which was
found to be more invasive (Fig. 2).
Pathogenicity of the PRN-negative B. parapertussis isolates
in the murine respiratory infection model
FR3728 (PRN-negative), BPPI (PRN-positive) and the refer-
ence strain 12822 had similar LD50s (1 · 108) for 4-week-old
Swiss mice (data not shown).
The infection profiles of FR3728 (PRN-negative) and BPP1
(PRN-positive) were similar to that of the reference strain
12822; all isolates were able to multiply and to colonize the
respiratory tract of young mice (Fig. 3).
Discussion
The number of B. parapertussis isolates collected by the French
NCR since 1993 is lower than the number of B. pertussis iso-
lates collected. However, surprisingly, the B. parapertussis iso-
lates collected since 2007 do not express one of the major
adhesins, PRN. This is because of a single base deletion within
region I or region II of the prn gene. Diavatopoulos et al. [23]
showed that the polymorphism in codon 187 in the prn gene
may be the result of immune competition between B. pertussis
and human B. parapertussis. None of the mutations that we
describe affects this codon. For both isolates PRN–negative,
region I and II determining amino acid polymorphism are iden-
tical to that of PRN-positive isolates (4a for region I and 9b for
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region II). However, PRN-negative isolates present point
mutations located very close to but outside the sequence-
determining amino acid polymorphism.
Sequencing of the genome of one PRN-negative and one
PRN-positive isolate did not identify any region of difference
(RD). This is in accordance with the findings of Brinig [5],
who, using a pan-bordetella microarray, detected no RD
between 28 human B. parapertussis isolates. One of the few
sequence differences that we found between the genomes of
both FR3728 (PRN-negative) and BPP1 (PRN-positive) and
the genome of the reference strain maps in brkB, located in
the locus implicated in serum resistance. Another maps in
bscR, located in the bsc locus implicated in the TTSS III. How-
ever, the TTSS III is not expressed in human B. parapertussis
isolates, because of the presence of two pseudogenes [4].
No genetic difference was found in the genes encoding
LPS. Specific serum of mice infected by B. parapertussis
detected LPS similarly in PRN-positive and PRN-negative
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FIG. 1. Genomic analysis of Bordetella
parapertussis isolates: chromosomal
DNA profiles obtained after digestion
with XbaI; the name of the isolates; the
country; the year of collection.
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isolates (data not shown). However, this does not rule out
structural differences in lipid A resulting from subtle differ-
ences in enzyme expression.
The cyaA gene did not differ between isolates, confirming
previous observations [24]. However, our genomic analysis
does not exclude the possibility of other differences, particu-
larly because AC-Hly is a post-translationally modified toxin
[25]. It is not known whether these modifications are similar
in all isolates.
No difference was observed between PRN-negative and
PRN-positive isolates concerning the regulation of expression
of the major toxins and adhesins, suggesting that this regula-
tion is important for the pathogenicity of the bacterium.
PRN-positive and PRN-negative isolates exhibit similar path-
ogenicity in a respiratory murine model: they exhibit similar
LD50s and are able to colonize the respiratory tract of the
mice. These findings are consistent with clinical observations.
We show that, unlike B. pertussis, B. parapertussis is not
cytotoxic for macrophages via necrosis, as the TTSS III is not
expressed, as suggested previously [26], and not via apopto-
sis, AC-Hly is expressed. Possible explanations for this major
difference between the two species are as follows: (i) there
is no sequence difference in the gene encoding AC-Hly in all
isolates, but there are several in the part encoding the
domain of AC-Hly responsible for the species-specific
protective immunity [25] and for the binding of the toxin to
its human receptor CD11b [27]—decreased or defective
TABLE 2. 454GS-FLX pyrosequencing data
BPP1 FR3728 (PRN-negative)
No. of sequences obtained 261 476 267 865
No. of sequences assembled 254 700 260 614
No. of sequences designed as repeats (%Newbler) 6643 (2.5) 6363 (2.38)
No. of sequences unmapped 133 116
No. of contigs 1563 1708
Mean size of contigs 3531 3327
Assembly size (bp) 4 409 442 4 403 127
% of sequences corresponding to the sequences of
the reference genome 12822
92 92
Coverage* 14X 14X
Total number of sequence differences from the
reference genome 12822
42 46
Common differences 15
Location details: four in non-coding regions, four
in genes encoding putative or hypothetical proteins,
two in genes encoding proteins involved in transport,
one in a gene encoding a regulatory protein, three in
genes encoding proteins involved in metabolism, and
one in gene brkB (Bordetella resistance to serum killing)
Specific differences 27 31
Location details: six in non-coding regions, nine in genes
encoding putative or hypothetical proteins, one in a
gene encoding a protein involved in transport, one in
a gene encoding a regulatory protein, and nine in
genes encoding proteins involved in metabolism
Location details: six in non-coding regions,
11 in genes encoding putative or hypothetical
proteins, one in a gene encoding a protein
involved in transport, one in a gene encoding
a regulatory protein, one in a gene encoding
a protein involved in metabolism, and one
corresponding to gene bscR
* number of times that one sequence is read.
FIG. 2. Invasive properties of different Bordetella parapertussis isolates.
Invasion of human tracheal epithelial (HTE) cells was performed with
12822, BPP1 (PRN-positive), FR3728 (PRN-negative), FR3717 (PRN-
negative), FR3743 (PRN-negative), FR3772 (PRN-negative), FR3286
(PRN-positive) and FR0388 (PRN-positive). Each isolate was added to
one well in a 24-well tissue culture plate containing at least 105 cells/
mL, such that the bacterium/cell ratio was 100 : 1. The invasion of
HTE cells was assayed as described in Materials and Methods. Invasion
by each isolate is reported relative to that of the B. parapertussis refer-
ence strain 12822. Values are the means and standard deviations of at
least three experiments.
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binding of the toxin to this receptor may explain the absence
of cytotoxicity of B. parapertussis; (ii) the post-translational
modification of AC-Hly may be different in the two species;
and (iii) interaction between LPS and AC-Hly may determine
the conformation of AC-Hly and its activity—LPS may, for
example, suppress the capacity of AC-Hly to induce macro-
phage apoptosis. These possibilities are under investigation.
We confirmed that B. parapertussis isolates are invasive in
epithelial cells but, unlike with B. pertussis [28], the non-
expression of PRN does not enhance the invasive properties.
In fact, the non-expression of AC-Hly enhances the invasive
properties of B. pertussis [28]. This does not seem to be the
case with B. parapertussis. However, the action of AC-Hly in
B. parapertussis may be impaired by LPS or different post-
translational modifications, as described above. As shown in
Results, one PRN-positive isolate is significantly more inva-
sive, and is under investigation.
All PRN-negative isolates described in this study were col-
lected from patients with whooping cough symptoms. It
seems that there is no clinical evidence for a role for PRN in
the virulence of B. parapertussis. However, a detailed analysis
of the clinical characteristics of patients infected with PRN-
positive or PRN-negative isolates is needed. The striking
observation is that these isolates are suddenly circulating in
France at the same time as some PRN-negative B. pertussis
isolates [21]. Pertussis vaccine coverage has increased over
the last 10 years, following the introduction of boosters.
Pertussis acellular vaccines target the virulence of the patho-
gen. Possibly, as vaccine coverage is increasing, the virulence
of the pathogen may be controlled, and isolates not express-
ing vaccine antigens will emerge and circulate. Indeed, PT-
negative or PRN-positive B. pertussis isolates are already
being collected in France (about 7% in 2009) [21]. We are
not expecting the same control of B. parapertussis isolates, as
purified B. pertussis antigens do not induce protective immu-
nity against B. parapertussis infections [15] in a murine respi-
ratory model. Similarly, neither B. pertussis infection nor
vaccination with pertussis whole cellular vaccine induces pro-
tective immunity in the field [17,18]. The appearance of
PRN-negative isolates may simply be attributable to contin-
uing adaptation of B. parapertussis to humans. Although PRN
is important in the virulence of B. pertussis and B. bronchisepti-
ca [28,29], our results obtained with cellular or animal mod-
els suggest that this does not seem to be the case for the
virulence of B. parapertussis.
In conclusion, the sudden emergence in France of PRN-
negative B. parapertussis isolates may correspond to: (i) clonal
expansion, as was observed for B. holmesii in Massachussets
[30]; or (ii) continued specific adaptation of B. parapertussis
to humans. If this phenomenon is indeed a result of adapta-
tion, it indicates that PRN expression is not required by
B. parapertussis during its interaction with its host.
It is unlikely, even though pertussis vaccine coverage has
increased recently in France in adolescents and adults, that
vaccine-induced immunity is affecting B. parapertussis inci-
dence, as the bacterium is not supposed to be sensitive to
this immunity. These issues and the evolution of the B. per-
tussis and B. parapertussis populations causing whooping
cough indicate that active surveillance of cases is necessary
and should continue.
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